Clevudine Induced Mitochondrial Myopathy

Soo-Hyun Park,1 Kyung-Seok Park,2 Nam-Hee Kim,1 Joong-Yang Cho,2 Moon Soo Koh,4 and Jin Ho Lee4

1Department of Neurology, Dongguk University Ilsan Hospital, Goyang, Korea; 2Department of Neurology, Seoul National University College of Medicine, Seoul, Korea; 3Department of Neurology, Inje University Ilsan Paik Hospital, Inje University College of Medicine, Goyang, Korea; 4Department of Hepatology, Dongguk University Ilsan Hospital, Goyang, Korea

Received: 20 January 2017
Accepted: 29 July 2017

Address for Correspondence:
Nam-Hee Kim, MD, PhD
Department of Neurology, Dongguk University Ilsan Hospital, 26 Dongguk-ro, Ilsandong-gu, Goyang 10326, Republic of Korea
E-mail: nheekim8@hanmail.net

Clevudine was approved as an antiviral agent for hepatitis B virus, which showed marked, rapid inhibition of virus replication without significant toxicity. However, several studies have reported myopathy associated with clevudine therapy. Also, we experienced seven patients who suffered from myopathy during clevudine therapy. To characterize clevudine-induced myopathy, we collected previously reported cases of clevudine myopathy and analyzed all the cases including our cases. We searched electronic databases that were published in English or Korean using PubMed and KoreaMed. Ninety-five cases with clevudine myopathy, including our seven cases, were selected and analyzed for the demographic data, clinical features, and pathologic findings. The 95 patients with clevudine-induced myopathy comprised 52 women and 43 men aged 48.9 years (27–76 years). The patients received clevudine therapy for about 14.2 months (5–24 months) before the development of symptoms. Weakness mainly involved proximal extremities, especially in the lower extremities, and bulbar and neck weakness were observed in some cases (13.7%). Creatine kinase was elevated in the majority of patients (97.9%). Myopathic patterns on electromyography were observed in most patients examined (98.1%). Muscle biopsy presented patterns compatible with mitochondrial myopathy in the majority (90.2%). The weakness usually improved within about 3 months after the discontinuation of clevudine. Though clevudine has been known to be safe in a 6-month clinical trial, longer clevudine therapy for about 14 months may cause reversible mitochondrial myopathy. Careful clinical attention should be paid to patients with long-term clevudine therapy.

Keywords: Clevudine; Antiviral Agent; Hepatitis B; Mitochondrial Myopathy; Myopathy

INTRODUCTION

Hepatitis B virus (HBV) is a leading cause of chronic hepatitis, cirrhosis, and hepatocellular carcinoma worldwide (1). Antiviral drug use is considered for chronic HBV infection treatment to prevent its serious sequelae. HBV is a deoxyribonucleic acid (DNA) virus. HBV replication relies on reverse transcription, which is similar to that of the human immunodeficiency virus (HIV) (1). Because of these characteristics, the majority of antiviral drugs are nucleoside and nucleotide analogs that interfere with viral replication by inhibiting viral DNA polymerase (1). However, their therapeutic effects are limited owing to drug resistance, relapse after treatment cessation, and possible toxicity (2). Mitochondrial cytotoxicity is a well-known side effect of nucleoside analogs. Thus, newer L-nucleoside analogs with no significant mitochondrial toxicity were introduced.

Clevudine (Reoviriv, 1-[2-deoxy-2-fluoro-b-Larabinofuranosyl] thymine, L-FMAU) which is an L-nucleoside analog for HBV was approved in Korea after a 24-week clinical trial with safety on mitochondrial structure, DNA content, or function (3,4). The advantage of clevudine is prolonged viral replication suppression even after withdrawal of treatment (3,4). Clevudine was approved in the Philippines and Korea, with incomplete licensing in Indonesia, Thailand, India, and Malaysia for the treatment of hepatitis B treatment (5).

In contrast to the clinical trial, several recent studies have reported myopathy associated with mitochondrial toxicity during clevudine therapy (6-8). We also experienced seven patients with myopathy during clevudine therapy. Therefore, we collected and summarized the reported cases, including our cases, to characterize the clinical features and laboratory findings of clevudine-induced myopathy for early detection.

MATERIALS AND METHODS

We conducted a PubMed and KoreaMed database search. Nighty-five cases of patients with clevudine myopathy, including our seven cases, were collected for the analysis (6-13). Our seven patients were recruited from January 2006 to June 2015 at two university hospitals. This retrospective study was approved by the local Human Research Protection Office/Institutional Review.

We assessed age, sex, clinical features, clevudine therapy duration before symptom onset, daily clevudine dose, and recov-
ery time. Recovery time was defined as the duration between discontinuation of clevudine and improvement to normal muscle power. Muscle power was graded using the Medical Research Council (MRC) scale. Bulbar symptoms or neck muscle weakness was also evaluated. Laboratory tests, including liver and renal function tests and creatine kinase (CK) levels, and available results of electrophysiological studies and muscle biopsies were analyzed.

Data were analyzed using the SPSS 20.0 (SPSS Inc., Chicago, IL, USA). Results were expressed as the mean with standard error or median with ranges. Univariate analysis was performed using Student’s t-test for continuous variables, and χ² and Fisher exact tests were used for categorical variables and correlation analysis. \( P < 0.05 \) was considered as significant.

**Ethics statement**

The present study protocol was reviewed and approved by the Institutional Review Board of Dongguk University Ilsan Hospital (registration No. 2016-116). Informed consent was submitted by all subjects when they were enrolled.

**RESULTS**

The clinical characteristics of 95 patients are presented in Table 1. The patients comprised 52 women and 43 men, aged 48.9 ± 9.1 years (range: 27–76 years). All patients were administered clevudine therapy (30 mg/day) for the treatment of chronic hepatitis B. The concurrently prescribed medications in the patients previously reported were not identified but all of our seven patients did not use drugs such as statins that could cause myopathy. The patients were treated with clevudine for 14.2 ± 3.9 months (range: 5–24 months) before the development of symptoms. Weakness gradually progressing to nadir took 8.6 ± 7.5 months in our seven patients. The common presenting symptom was extremity weakness. Weakness involved the lower and upper extremities in 98.1% and 75.9% of the patients, respectively. In addition, lower extremity weakness was more severe in the proximal part (mean MRC grade: 3.7) than the distal part (mean MRC grade: 4.3, \( P < 0.001 \)). Upper extremity weakness was also more severe in the proximal part (mean MRC grade: 4.5) than the distal part (mean MRC grade: 4.8, \( P < 0.001 \)). Bulbar and neck weakness were found in 13 patients (13.7%), with no ocular muscle involvement. Myalgia was sometimes accompanied with progressive weakness (Table 1).

Laboratory findings are summarized in Table 2. Serum CK level was elevated (median: 887.7 IU/L, range: 117.0–8,082.0 IU/L) in the majority of patients (97.9%). The mean lactate dehydrogenase level was also elevated (788.6 ± 409.6, range: 205.0–2,919.0 IU/L). The mean aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels were 72.2 ± 52.6 IU/L and 41.5 ± 17.6 IU/L, respectively. The ratio of serum AST to ALT levels (1.76 ± 0.80) was disproportionately high in 97%. Eighty-five patients (89.5%) showed elevation in one of these two liver function tests. Myopathic patterns on electromyography (EMG) were observed in 53 patients (98.1%) among 54 patients who underwent EMG with normal nerve conduction studies. Muscle biopsies from 41 patients, including two in our seven patients, showed characteristic findings of myonecrosis,ragged red fibers, cytochrome-c-oxidase-negative fibers, type 2 fiber atrophy, or abnormal mitochondria in most cases (90%), except four patients with only inflammatory changes (Fig. 1) (5-9).

Weakness gradually improved within 11.8 ± 5.8 weeks (range: 2–36 weeks) after discontinuation of clevudine without significant sequelae in all patients (Table 1).

**Table 1. Summary of demographic, clinical features, and laboratory findings of the patients**

| Characteristics                        | Values                        |
|----------------------------------------|-------------------------------|
| Age, yr                                | 48.9 ± 9.1 (27–76)            |
| Sex (male:female)                      | 43:52                         |
| Duration of clevudine therapy before symptom onset, mon | 14.2 ± 3.9 (5–24)            |
| Time to nadir of weakness in our seven cases, mon | 8.6 ± 7.5 (3–24)            |
| Distribution of weakness, No. of patients |                               |
| Bulbar or neck                         | 13 (13.7)                     |
| Arm                                    | 69 (72.6)                     |
| Proximal arm/distal arm                | 66/50                         |
| Leg                                    | 94 (98.9)                     |
| Proximal leg/distal leg                | 86/57                         |
| Grade of weakness, MRC grade           |                               |
| Proximal/distal, arm                   | 4.5 ± 0.4/4.8 ± 0.4           |
| Proximal/distal, leg                   | 3.7 ± 0.4/4.3 ± 0.5           |
| Myalgia, No. of patients               | 12 (12.6)                     |
| Recovery from discontinuation of clevudine, wk | 11.8 ± 5.8 (2–36)           |
| Elevated CK, No. of patients           | 93 (97.9)                     |
| Elevated liver enzymes (AST or ALT), No. of patients | 85 (98.5) |

Values are presented as mean ± standard deviation (range) or number (%).

**Table 2. Laboratory, EMG, and pathological findings**

| Characteristics                        | Values                        |
|----------------------------------------|-------------------------------|
| CK, IU/L                               | 887.7 (117.0–8,082.0)        |
| AST, IU/L                              | 72.2 ± 52.6 (23.0–475.0)     |
| ALT, IU/L                              | 41.5 ± 17.6 (12.0–123.0)     |
| LDH, IU/L                              | 788.6 ± 409.6 (205.0–2,919.0) |
| Pathological findings (frequency), No. of abnormalities/No. of biopsies |                   |
| Myonecrosis                            | 38/41 (92.7)                 |
| Ragged red fibers                      | 29/41 (70.7)                 |
| Abnormal mitochondria on EM            | 35/41 (85.4)                 |
| Abnormal EMG findings (frequency), No. of abnormalities/No. of EM done | 53/54 (98.1) |

Values are presented as median (range) or mean ± standard deviation (range), or number (%). EMG = electromyography, CK = creatine kinase, AST = aspartate aminotransferase, ALT = alanine aminotransferase, LDH = lactate dehydrogenase, EM = electron microscopy.
Correlation analysis demonstrated that age, sex, CK, muscle weakness severity, or clevudine therapy duration was not associated with the recovery time from clevudine-induced myopathy.

**DISCUSSION**

Previous clinical trials have evaluated the safety and efficacy of clevudine for 6 months in patients with chronic hepatitis B and reported no adverse effects on muscle. However, 95 patients, including our seven patients, showed that long-term clevudine therapy could cause a reversible mitochondrial myopathy with progressive weakness in the proximal lower extremities. From January 2006 to June 2015, five cases of clevudine myopathy developed among 177 patients who were treated with clevudine in our university hospital. It could be estimated as an incidence rate of 2.8% for clevudine-induced myopathy. In the literature, the incidence rate of myopathy was estimated to be 3.9%–14.4% in patients who were administered clevudine (8,11-14).

No in vitro and in vivo studies demonstrate the possible mechanism of clevudine-induced myopathy. The mechanism of myopathy induced by zidovudine for HIV, which is also a nucleoside analog reverse-transcriptase inhibitor similar to clevudine, would be similar to that of clevudine myopathy. The use of zidovudine has indicated that apoptosis of skeletal muscle cells can be caused by direct mitochondrial DNA depletion, mitochondrial dysfunction, oxidative stress, and L-carnitine depletion (15). Zidovudine causes damage to mitochondria by impairment of respiratory chain and mitochondrial protein synthesis (16). Recently, telbivudine, another L-nucleoside analogue for HBV infection, has been reported to show evidence of mitochondrial toxicity with a clinical pattern similar to that of fifteen patients (17).

The clinical symptoms of myopathy developed after approximately 14.2 months of clevudine treatment. Clevudine-associated myopathy was characterized by clinical features of subacute progressive weakness in the proximal lower extremities with elevated CK levels. These clinical features might be misdiagnosed as polymyositis. In fact, two of 95 patients, one reported case (8) and one of our seven cases were initially diagnosed with polymyositis. Thus, they were treated with steroid for a few weeks. Steroid had no effect on these two patients with clevudine myopathy. These cases have shown that it is important to know the drugs that cause myopathy such as clevudine to prevent unnecessary workup and treatments.

Decreased motor function in the proximal lower extremity was the most common clinical manifestation in our study. However, bulbar dysfunction or neck weakness also could appear in clevudine myopathy. Clinical symptoms of myopathy improved
within 11.8 weeks after clevudine discontinuation. Clevudine therapy discontinuation seems to be an appropriate management for the recovery from myopathy (3,18).

Although we summarized the typical characteristics of clevudine-induced myopathy by analyzing all the previous cases of clevudine myopathy, including our seven cases, this study has some limitations, such as not assessing the risks or predisposing factors for clevudine myopathy. Further studies are needed to identify the risk or predisposing factors for the occurrence of myopathy during clevudine medication through the comparative analysis between the myopathy group and non-myopathy group.

We should be assured by monitoring motor weakness and serum muscle enzyme levels under the medication of clevudine to detect clevudine-induced myopathy. In addition, in the case of acute or subacute myopathies, a detailed history of medications including nucleoside analogs such as clevudine should be carefully checked so as not to miss the diagnosis of drug-induced myopathy.

DISCLOSURE

The authors have no potential conflicts of interest to disclose.

AUTHOR CONTRIBUTION

Conceptualization: Park SH, Kim NH. Data curation: Park KS, Kim NH, Koh MS, Lee JH. Formal analysis: Park KS, Kim NH. Investigation: Park SH, Park KS, Kim NH, Cho JY. Writing - original draft: Park SH, Kim NH. Writing - review & editing: Park SH, Park KS, Kim NH, Cho JY.

ORCID

Soo-Hyun Park https://orcid.org/0000-0003-1626-3940
Kyung-Seok Park https://orcid.org/0000-0003-1553-5932
Nam-Hee Kim https://orcid.org/0000-0001-7985-5877
Joong-Yang Cho https://orcid.org/0000-0002-5916-3846
Moon Soo Koh https://orcid.org/0000-0002-3534-8459
Jin Ho Lee https://orcid.org/0000-0002-8013-3262

REFERENCES

1. Lam YE, Yuen ME, Seto WK, Lai CL. Current antiviral therapy of chronic hepatitis B: efficacy and safety. Curr Hepat Rep 2011; 10: 235-43.
2. Lok AS, McMahon BJ, Brown RS Jr, Wong JB, Ahmed AT, Farah W, Almasri J, Alahdab F, Benkhadra K, Mouchall MA, et al. Antiviral therapy for chronic hepatitis B viral infection in adults: a systematic review and meta-analysis. Hepatology 2016; 63: 284-306.
3. Korbis BE, Furman PA, Otto MJ. Clevudine: a potent inhibitor of hepatitis B virus in vitro and in vivo. Expert Rev Anti Infect Ther 2006; 4: 549-61.
4. Yoo BC, Kim JH, Chung YH, Lee KS, Park SW, Ryu SH, Han BH, Han JY, Byun KS, Cho M, et al. Twenty-four-week clevudine therapy showed potent and sustained antiviral activity in HBcAg-positive chronic hepatitis B. Hepatology 2007; 45: 1172-8.
5. Manzoor S, Saalim M, Imran M, Resham S, Ashrafi J. Hepatitis B virus therapy: what’s the future holding for us? World J Gastroenterol 2015; 21: 12558-75.
6. Seok JL, Lee DK, Lee CH, Park MS, Kim SY, Kim HS, Jo HY, Lee CH, Kim DS. Long-term therapy with clevudine for chronic hepatitis B can be associated with myopathy characterized by depletion of mitochondrial DNA. Hepatology 2009; 51: 2080-6.
7. Kim BK, Oh J, Kwon SY, Choek WH, Ko SY, Rhee KH, Seo TH, Lim SD, Lee CH. Clevudine myopathy in patients with chronic hepatitis B. J Hepatol 2009; 51: 829-34.
8. Kim JY, Yoon YS, Park KD, Koo H. Myopathy due to chronic clevudine therapy: a case report. Korean J Pathol 2009; 43: 575-9.
9. Yang CY, Park SA, Kim HS, Shin YI. Polymyositis in patients taking antiviral clevudine therapy: a report of two cases. NeuroRehabilitation 2010; 26: 159-62.
10. Seok JI, Kim DS, Park MS, Nam TS, Song HS, Park YE, Kim SY, Kim YS, Huh SY, Lee DK, et al. Clinical and pathological features of clevudine induced myopathy. J Korean Neurol Assoc 2013; 31: 26-31.
11. Lee JW, Lee YJ, Lee JY, Kim JH, Jung YK, Kwon OS, Choi DJ, Kim YS, Kim JH. Efficacy of entecavir switching therapy in chronic hepatitis B patients with clevudine-induced myopathy. Korean J Gastroenterol 2013; 61: 30-6.
12. Tak WY, Park SY, Cho CM, Jung MK, Jeon SW, Kweon YO, Park JY, Sohn YK. Clinical, biochemical, and pathological characteristics of clevudine-associated myopathy. J Hepatol 2010; 53: 261-6.
13. Jang JH, Kim JW, Jeong SH, Myung HJ, Kim HS, Park YS, Lee SH, Hwang JH, Kim N, Lee DH. Clevudine for chronic hepatitis B: antiviral response, predictors of response, and development of myopathy. J Viral Hepat 2011; 18: 84-90.
14. Yoon EL, Yim HJ, Lee HJ, Lee YS, Kim JH, Jung ES, Kim JH, Seo YS, Yeon JE, Lee HS, et al. Comparison of clevudine and entecavir for treatment-naive patients with chronic hepatitis B virus infection: two-year follow-up data. J Clin Gastroenterol 2011; 45: 893-9.
15. Scruggs ER, Dirks Naylor AJ. Mechanisms of zidovudine-induced mitochondrial toxicity and myopathy. Pharmacology 2008; 82: 83-8.
16. Masini A, Scotti C, Calligaro A, Cazzalini O, Stivala LA, Bianchi L, Giovaninni F, Ceccarelli D, Muscatello U, Tomasi A, et al. Zidovudine-induced experimental myopathy: dual mechanism of mitochondrial damage. J Neural Sci 1999; 166: 131-40.
17. Ambang T, Tan JS, Ong S, Wong KT, Koh KJ. Clinicopathological features of Telbivudine-associated myopathy. PLoS One 2016; 11: e0162760.
18. Gwak GY, Eo SJ, Shin SR, Choi MS, Lee JH, Koh KC, Park SW, Yoo BC. A comparison of clevudine and entecavir for treatment-naive patients with chronic hepatitis B: results after 2 years of treatment. Hepatol Int 2013; 7: 106-10.